Answers are grounded in this paper and cite their sources.
Non-nutritive sweeteners (NNS) have become widespread dietary components in response to concerns about excessive sugar consumption, obesity, type 2 diabetes, and related metabolic disorders. Although traditionally considered metabolically inert, emerging evidence indicates that NNS may exert biological effects. This review examines the pharmacokinetics and receptor-binding mechanisms of natural (steviol glycosides, mogrosides, and thaumatin) and artificial (aspartame, saccharin, sucralose, acesulfame potassium, neotame, and advantame) NNS, with emphasis on their interaction with the T1R2/T1R3 sweet taste receptor complex and downstream signaling pathways. We further explore how NNS may alter gut microbiota composition, short-chain fatty acid production, and bile acid metabolism, potentially affecting intestinal barrier integrity and immune homeostasis in a compound- and context-dependent manner. Emerging evidence also suggests that NNS-associated dysbiosis may influence epigenetic and epitranscriptomic mechanisms, including DNA methylation, histone modifications, microRNA regulation, and m6A RNA modification, with potential consequences for inflammatory, metabolic, vascular, and neuroinflammatory pathways. Integrating human, animal, in vitro, and structural evidence, this review highlights the biological diversity of NNS and indicates that their effects are neither uniformly inert nor harmful. Outcomes appear dependent on sweetener characteristics, dietary context, microbiota composition, and host metabolic status. Further longitudinal, multi-omics human studies are needed to clarify their long-term clinical implications.
No takes yet. Share an insight, caveat, or question.
Ganoub et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: